BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35267442)

  • 1. Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer.
    Rack S; Feeney L; Hapuarachi B; Adderley H; Woodhouse L; Betts G; Burghel GJ; Harrington KJ; Metcalf R
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.
    Thierauf J; Ramamurthy N; Jo VY; Robinson H; Frazier RP; Gonzalez J; Pacula M; Dominguez Meneses E; Nose V; Nardi V; Dias-Santagata D; Le LP; Lin DT; Faquin WC; Wirth LJ; Hess J; Iafrate AJ; Lennerz JK
    Oncologist; 2019 Oct; 24(10):1356-1367. PubMed ID: 30926674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?
    Cavalieri S; Platini F; Bergamini C; Resteghini C; Galbiati D; Bossi P; Perrone F; Tamborini E; Quattrone P; Licitra L; Locati LD; Alfieri S
    Expert Opin Investig Drugs; 2019 May; 28(5):435-443. PubMed ID: 30897975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.
    Adderley H; Rack S; Hapuarachi B; Feeney L; Morgan D; Hussell T; Wallace AJ; Betts G; Hodgson C; Harrington K; Metcalf R
    Oral Oncol; 2021 Feb; 113():105095. PubMed ID: 33290961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients.
    Porter A; Natsuhara M; Daniels GA; Patel SP; Sacco AG; Bykowski J; Banks KC; Cohen EEW
    Transl Cancer Res; 2020 Jan; 9(1):203-209. PubMed ID: 35117174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.
    Ross JS; Gay LM; Wang K; Vergilio JA; Suh J; Ramkissoon S; Somerset H; Johnson JM; Russell J; Ali S; Schrock AB; Fabrizio D; Frampton G; Miller V; Stephens PJ; Elvin JA; Bowles DW
    Ann Oncol; 2017 Oct; 28(10):2539-2546. PubMed ID: 28961851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
    Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
    Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
    Pezo RC; Chen TW; Berman HK; Mulligan AM; Razak AA; Siu LL; Cescon DW; Amir E; Elser C; Warr DG; Sridhar SS; Yu C; Wang L; Stockley TL; Kamel-Reid S; Bedard PL
    Breast Cancer Res Treat; 2018 Feb; 168(1):159-168. PubMed ID: 29177603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
    Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
    Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
    [No Abstract]   [Full Text] [Related]  

  • 11. Genomic landscape of salivary gland tumors.
    Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R
    Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial.
    Hernando-Calvo A; Malone E; Day D; Prawira A; Weinreb I; Yang SYC; Wong H; Rodriguez A; Jennings S; Eliason A; Wang L; Spreafico A; Siu LL; Hansen AR
    Cancer Med; 2023 Oct; 12(20):20299-20310. PubMed ID: 37818869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.
    Colomer R; Miranda J; Romero-Laorden N; Hornedo J; González-Cortijo L; Mouron S; Bueno MJ; Mondéjar R; Quintela-Fandino M
    EClinicalMedicine; 2023 Jun; 60():102029. PubMed ID: 37304496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
    Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
    Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients.
    Lassche G; van Helvert S; Eijkelenboom A; Tjan MJH; Jansen EAM; van Cleef PHJ; Verhaegh GW; Kamping EJ; Grünberg K; van Engen-van Grunsven ACH; Ligtenberg MJL; van Herpen CML
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077692
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
    Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
    BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary gland carcinoma: Towards a more personalised approach.
    Rached L; Saleh K; Casiraghi O; Even C
    Cancer Treat Rev; 2024 Mar; 124():102697. PubMed ID: 38401478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.
    Morris LGT; Chandramohan R; West L; Zehir A; Chakravarty D; Pfister DG; Wong RJ; Lee NY; Sherman EJ; Baxi SS; Ganly I; Singh B; Shah JP; Shaha AR; Boyle JO; Patel SG; Roman BR; Barker CA; McBride SM; Chan TA; Dogan S; Hyman DM; Berger MF; Solit DB; Riaz N; Ho AL
    JAMA Oncol; 2017 Feb; 3(2):244-255. PubMed ID: 27442865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.
    de Sousa LG; Jovanovic K; Ferrarotto R
    Curr Treat Options Oncol; 2022 Aug; 23(8):1135-1150. PubMed ID: 35854180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.